West Virginia 2026 Session Status: Introduced 7 R cosponsors

HB 4626 — Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine

Last action — Vetoed by Governor 4/1/2026 - House Journal

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House of Delegates
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2026 Session. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

Vetoed by Governor Patrick Morrisey (Republican) on March 14, 2026.

This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.

Summary

Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine

Bill Text

What changed in the latest version

48 added · 29 removed

Plain-language change summary

The amendments to Bill HB 4626 include specific guidelines for conducting drug development trials using ibogaine, a potential treatment for opioid use disorder. Key changes involve clarifying the roles of parties responsible for oversight and the process for securing insurance coverage for ibogaine treatment. These updates are important because they help ensure that the trials are conducted effectively and safely, ultimately aiming to make this treatment accessible to those who need it.

→
Previous
Latest
WEST VIRGINIA LEGISLATURE REGULAR SESSION ENGROSSED House Bill 4626 By Delegates Browning, Worrell, Burkhammer, Dean, Hillenbrand, Hite, and Heckert [Introduced January 21, 2026;
WEST VIRGINIA LEGISLATURE REGULAR SESSION ENROLLED House Bill 4626 BY DELEGATES BROWNING , WORRELL, URKHAMMER , DEAN, HILLENBRAND, IT,AND H ECKERT [Passed March 12, 2026;
referred to the Committee on Health and Human Resources] Eng HB 4626 A BILL to amend the Code of West Virginia, 1931, as amended, by adding a new article, designated §16-67-1, §16-67-2, §16-67-3, §16-67-4, §16-67-5, §16-67-6, and §16-67-7, relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine;
in effect 90 days from passage (June 10, 2026)] Enr HB 4626 AN ACT to amend the Code of West Virginia, 1931, as amended, by adding a new article, designated §16-67-1, §16-67-2, §16-67-3, §16-67-4, §16-67-5, §16-67-6, and §16-67-7, relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine;
Eng HB 4626 (1) Be a for-profit, nonprofit, or public benefit corporate entity that has the requisite organizational and financial capacity to:
Enr HB 4626 (1) Be a for-profit, nonprofit, or public benefit corporate entity that has the requisite organizational and financial capacity to:
(ii) Administration protocols;
(ii) Administration protocols;
Eng HB 4626 (iii) Treatment models or techniques;
Enr HB 4626 (iii) Treatment models or techniques;
and (iv) Technology used in the trials;
and (iv) Technology used in the trials;
(E) A plan to secure third-party payor approval for ibogaine treatment following approval by the United States Food and Drug Administration through:
(E) A plan to secure third-party payor approval for ibogaine treatment following approval by the United States Food and Drug Administration through:
(ii) Medicare;
(ii) Medicare;
(iii) Medicaid;
(iii) Medicaid;
Eng HB 4626 (b) The selection committee shall review applications, communicate supplemental inquiries to applicants, and recommend to the secretary the best applicants to conduct the drug development trials.
Enr HB 4626 (b) The selection committee shall review applications, communicate supplemental inquiries to applicants, and recommend to the secretary the best applicants to conduct the drug development trials.
(a) As soon as practicable after drug development trial sites are established under §16-67- 5 of this code, the applicant shall begin a drug development trial to administer treatment with ibogaine.
(a) As soon as practicable after drug development trial sites are established under §16- 67-5 of this code, the applicant shall begin a drug development trial to administer treatment with ibogaine.
(b) The secretary, in consultation with the selection committee under §16-67-3 of this code, shall select an institutional review board with a presence in this state to oversee and verify the drug development trial research activity for scientific validation and authentication under the requirements of the United States Food and Drug Administration.
(b) The secretary, in consultation with the selection committee under §16-67-3 of this code, shall select an institutional review board with a presence in this state to oversee and verify the drug development trial research activity for scientific validation and authentication under the requirements of the United States Food and Drug Administration.
Eng HB 4626 (c) The applicant shall request the designation under 21 U.S.C.
Enr HB 4626 (c) The applicant shall request the designation under 21 U.S.C.
(b) An applicant selected to perform a drug development trial under this chapter shall contribute toward the cost of developing the ibogaine treatment an amount of money that is at least equal to the amount of money that the applicant received in the form of a grant from the secretary.
(b) An applicant selected to perform a drug development trial under this chapter shall contribute toward the cost of developing the ibogaine treatment an amount of money that is at least equal to the amount of money that the applicant received in the form of a grant from the secretary.
Enr HB 4626 The Clerk of the House of Delegates and the Clerk of the Senate hereby certify that the foregoing bill is correctly enrolled.
...............................................................
Clerk of the House of Delegates ...............................................................
Clerk of the Senate Originated in the House of Delegates.
In effect 90 days from passage.
...............................................................
Speaker of the House of Delegates ...............................................................
President of the Senate __________ The within is ................................................
this the...........................................
Day of ..........................................................................................................., 2026.
.............................................................
Governor 7
⬇ Download PDF
View plain text versions (3)

Action History

  1. Filed for introduction

  2. To Health and Human Resources

  3. Introduced in House

  4. To House Health and Human Resources

  5. Markup Discussion

  6. Do pass

  7. On 1st reading, Special Calendar

  8. On 1st reading, Special Calendar

  9. Read 1st time

  10. On 2nd reading, Special Calendar

  11. Read 2nd time

  12. On 3rd reading, Special Calendar

  13. Read 3rd time

  14. Passed House (Roll No. 32)

  15. Communicated to Senate

  16. Introduced in Senate

  17. To Health and Human Resources then Finance

  18. To Health and Human Resources

  19. Reported do pass, but first to Finance

  20. To Finance

  21. Reported do pass

  22. On 1st reading

  23. Read 1st time

  24. On 2nd reading

  25. Read 2nd time

  26. On 3rd reading

  27. Read 3rd time

  28. Passed Senate (Roll No. 487)

  29. Communicated to House

  30. Completed legislative action

  31. House received Senate message

  32. To Governor 3/31/2026

  33. To Governor 3/31/2026 - Senate Journal

  34. Vetoed by Governor 4/1/2026 - Senate Journal

  35. Vetoed by Governor 4/1/2026

  36. Vetoed by Governor 4/1/2026 - House Journal

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 6 co-sponsors · 145 not signed on

Sponsors (1)

Co-sponsors (6)

Not signed on (145)

145 members have not signed on to this bill.

Show all 145 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

PASSAGE

Passed 96 Yea · 0 Nay · 3 Other
Party YeaNayPresentNot Voting
Republican 84003
Democrat 9000
Unaffiliated 3000
Total 96003
% of votes cast 97%0%0%3%
How each member voted (99)
Member Party Vote
Kump — Yea
Flanigan — Yea
Linville — Yea
Anitra Hamilton Democrat Yea
Evan Hansen Democrat Yea
Hollis Lewis Democrat Yea
John Williams Democrat Yea
Kayla Young Democrat Yea
Mike Pushkin Democrat Yea
Rick Garcia Democrat Yea
Sean Hornbuckle Democrat Yea
Shawn Fluharty Democrat Yea
Adam Burkhammer Republican Yea
Adam Vance Republican Yea
Andy Shamblin Republican Yea
Bill Bell Republican Yea
Bill Ridenour Republican Yea
Bob Fehrenbacher Republican Yea
Bryan Smith Republican Yea
Bryan Ward Republican Yea
Carl "Bill" Roop Republican Yea
Carl Martin Republican Yea
Charles Sheedy Republican Yea
Chris Phillips Republican Yea
Christopher W. Toney Republican Yea
Chuck Horst Republican Yea
Clay Riley Republican Yea
D. Rolland Jennings Republican Yea
Dana Ferrell Republican Yea
Dave Foggin Republican Not Voting
David Cannon Republican Yea
David Green Republican Yea
David McCormick Republican Yea
Dean Jeffries Republican Yea
Doug Smith Republican Not Voting
Elias Coop-Gonzalez Republican Yea
Eric Brooks Republican Yea
Erica Moore Republican Yea
Evan Worrell Republican Yea
Gary G. Howell Republican Yea
Geno Chiarelli Republican Yea
George Miller Republican Yea
George Street Republican Yea
Gregory A. Watt Republican Yea
Guy Ward Republican Yea
Henry Dillon Republican Yea
Ian T. Masters Republican Yea
James Robert "JB" Akers II Republican Yea
Jarred Cannon Republican Yea
Jeff Campbell Republican Yea
Jeff Eldridge Republican Yea
Jeffrey Stephens Republican Yea
Jim Butler Republican Yea
Jimmy Willis Republican Yea
Joe Ellington Republican Yea
Joe Funkhouser Republican Yea
Joe Parsons Republican Yea
Joe Statler Republican Yea
John Jordan Republican Yea
John Paul Hott Republican Yea
Jonathan Kyle Republican Yea
Jonathan Pinson Republican Yea
Jordan Bridges Republican Not Voting
Jordan Maynor Republican Yea
Josh Holstein Republican Yea
Kathie Hess Crouse Republican Yea
Keith Marple Republican Yea
Laura Kimble Republican Yea
Lisa White Republican Yea
Lori Dittman Republican Yea
Margitta Mazzocchi Republican Yea
Mark Dean Republican Yea
Mark Zatezalo Republican Yea
Marshall W. Clay Republican Yea
Marty Gearheart Republican Yea
Matthew Rohrbach Republican Yea
Michael Amos Republican Yea
Michael Hite Republican Yea
Michael Hornby Republican Yea
Mickey Petitto Republican Yea
Pat McGeehan Republican Yea
Patrick Lucas Republican Yea
Phil Mallow Republican Yea
Ray Canterbury Republican Yea
Rick Hillenbrand Republican Yea
Roger Hanshaw Republican Yea
Roy Cooper Republican Yea
Ryan Browning Republican Yea
S. Chris Anders Republican Yea
Sarah Drennan Republican Yea
Scot C. Heckert Republican Yea
Stanley Adkins Republican Yea
Tresa Howell Republican Yea
Tristan Leavitt Republican Yea
Vacant1 Republican Yea
Vernon Criss Republican Yea
Walter Hall Republican Yea
Wayne Clark Republican Yea
William Anderson Republican Yea

Official roll call →

Subjects

healthcare health-insurance technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 4626 do?
Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine
Who sponsors HB 4626?
HB 4626 is sponsored by Ryan Browning (Republican), Evan Worrell (Republican), Adam Burkhammer (Republican), Mark Dean (Republican), Rick Hillenbrand (Republican), Michael Hite (Republican), and Scot C. Heckert (Republican).
What is the current status of HB 4626?
This bill died with 2026 Session. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 4626?
Track HB 4626 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 4626

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 4626

Last checked for changes about 1 month ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →